TIRZEPATIDE

TIRZEPATIDE

Tirzepatide marks a new era in peptide-based therapeutics. Developed by Eli Lilly, this synthetic 39-amino-acid peptide is the first dual agonist targeting GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors. FDA-approved as Mounjaro (2022, type 2 diabetes) and Zepbound (2023, obesity), it delivers unprecedented 20–25% body weight loss—surpassing every prior drug class.

Development and Structure

Tirzepatide evolved from exendin-4 (GLP-1 base) + GIP analogs, engineered for balanced affinity (1:1 ratio). Fatty acid conjugation extends half-life to 5 days.

Pharmacology:

• GLP-1R: 97% activation → satiety, insulin ↑.
• GIPR: 82% → fat metabolism, beta-cell growth.
• Weekly subQ; bioavailability 85%.

How Tirzepatide Works: Dual Receptor Magic

1. Appetite/GE Control (GLP-1): Signals fullness via hypothalamus; slows emptying.
2. Insulin/Glucose (Both): Potentiates post-meal insulin, ↓glucagon.
3. Lipolysis/Adiposity (GIP): Brown fat activation, ↓visceral fat.
4. Neuroprotection: Brain GLP-1R for addiction/craving control.

Biomarker Shifts: ↓Leptin, ↑adiponectin; liver fat -80% (NASH).

Landmark Clinical Evidence

SURMOUNT-1 (Obesity, NEJM 2022)

SURMOUNT-2 (T2D + Obesity)

• 15mg: -14.7% vs. placebo -3.2%.

SURMOUNT-5 (vs. Semaglutide)

• Tirz: -20.2% vs. Sema -13.7% (36w).

Metabolic Wins: 90% NASH resolution; CV risk ↓.

Optimized Dosing Protocols

• Missed Dose: <4 days → next day; else skip.
• Lifestyle: 500kcal deficit + resistance training preserves muscle (20–30% loss typical).

Benefits: Beyond Weight Loss

1. Obesity: Class-leading; 1 in 4 lose >30%.
2. T2D: Remission in 50%+ (SURPASS).
3. NASH/MASH: Gold standard (SYNERGY-NASH).
4. Sleep Apnea: 50% resolution (SURMOUNT-OSA).
5. PCOS/PCOS-like: Insulin sensitivity ↑.
6. QoL: Hunger ↓85%, energy ↑.

Side Effects and Risk Mitigation

• Muscle Loss: Protein 1.6g/kg + exercise.
• Rebound: 2/3 regain off-drug; lifestyle key.

Comparisons: Tirzepatide vs. The Field

UK/EU Access and Status

• NHS: T2D (BMI>35); private weight loss.
• Shortages: Compounded (503B pharmacies).
• Cost: Private £200–300/month.

Future Pipeline

• Oral Tirz: Phase 3.
• Combos: +Cagrilintide (amycretin-like).
• Expansions: Heart failure, Alzheimer’s.

Conclusion: Tirzepatide’s Transformative Potential

Tirzepatide redefines metabolic health—dual agonism unlocks results once thought impossible. Paired with behavior, it’s a lifelong tool.